TKM.TO: Message Board for TEKMIRA PHARMACEUTICALS CORP | Forum profile

http://www.pharmabiz.com/article/detnews.asp?articleid=53348&sectionid =   Alnylam announces new pre-clinical research on systemic delivery of RNAi Therapeutics Thursday, December 31, 2009 18:00 IST Cambridge Alnylam Pharmaceuticals, Inc, a leading RNAi therapeutics company, and collaborators from the David H Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) announced the publication...

lipid-like materials...'lipid nano particles based on novel lipid like materials such as lipidoids.' Appears to be an effort to show(on some level)a derivative relationship between lipidoids and Tekmira's enabling lipid platform,imo. btw...has BMY already ended its collaboration which was due to expire at year end or might we get some clarity on the relationship in early January? msg 7506

Not to expect a release about TTR IND. I remember it very specifically. Look here for news: http://clinicaltrials.gov/ct2/results?term=alnylam J

Happy new year and thanks for all the post without you i sold a long time ago i think this is the year that we hit 3 bucks zutfie

If there was a fundamental flaw that we had overlooked, then I would not think that everybody is flocking to liposomal siRNA delivery, an area where Tekmira is the clear leader.  Dicerna has been on my list as potential strategic Tekmira partners, Kyowa Hakko now, too. Don't be fooled when you read that all these companies have liposomal efforts as with RNAi workforces of 20-40 spread thinly over RNAi trigger design and...